Some of the best links we picked up around the internet
At yesterday's CRISPRMED25 Virtual Event, five oral presenters and eleven poster contributors from academia and industry shared advances across a...
Scientists used lipid nanoparticles to deliver CRISPR-Cas9 targeting Hao1 for the treatment of primary hyperoxaluria type 1. Proof-of-concept studies...
YolTech Therapeutics reports positive clinical data for the first in vivo gene-editing therapy in primary hyperoxaluria type 1, Precision BioSciences...